Shareholders’ Deficit (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of Common Stock Reserved for Future Issuance

As of September 30, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

	Securities To Be Issued Upon Exercise Of Options		Securities To Be Issued Upon Release Of Restricted Stock		Number Of Remaining Securities Available For Future Issuance
2022 Inducement Equity Incentive Plan		7,595		1,317		181
2011 Equity Incentive Plan		1,594		6,305		4,983
2017 Inducement Award Plan		60		2		—
2017 Employee Stock Purchase Plan		—		—		1,782
Total common stock reserved for future issuance		9,249		7,624		6,946

Stock-based compensation expense is reported in the Company's condensed consolidated statement of operations as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Cost of product revenue	$	188	$	154	$	648	$	459
Research and development expense		459		610		1,241		2,014
Selling, general and administrative expense		2,739		3,730		7,759		10,726
Total stock-based compensation expense	$	3,386	$	4,494	$	9,648	$	13,199